Publication|Articles|November 18, 2026

Pharmacist-Led Initiative Enrolling Medicare-Eligible Patients in State Pharmaceutical Assistance Programs

Listen
0:00 / 0:00

Key Takeaways

  • Screening identified 38% initially eligible-but-not-enrolled patients, with 27% remaining eligible after follow-up, supporting systematic affordability assessments for brand-name GDMT during hospitalization and discharge planning.
  • Postdischarge telephone follow-up converted 11% of eligible patients to PACENET enrollment, indicating modest yield but meaningful benefit from low-intensity pharmacist outreach.
SHOW MORE

Identifying and screening Medicare Part D patients who are ordered brand-name cardiovascular medications for PACE/PACENET eligibility before discharge can reduce patients’ out-of-pocket costs for these medications.

Abstract

About the Authors

Gillian Dudeck, PharmD, is an ambulatory cardiology clinical pharmacist at Geisinger Medical Center in Danville, Pennsylvania.

Heather Goetze, PharmD, TTS, is a clinical pharmacy specialist at Allegheny Health Network in Pittsburgh.

Brittany Nolton, PharmD, BCACP, is a senior health outcomes pharmacist at Highmark Health in Pittsburgh.

Luke Gormley, PharmD, BCCP, is an associate medical liaison at AstraZeneca.

Disclosures

At the time of writing, Gormley was a clinical pharmacy specialist at Allegheny Health Network in Pittsburgh. This project received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Objectives

The primary objective of this project was to determine the percentage of patients eligible for but not enrolled in Pennsylvania’s medication assistance programs, Pharmaceutical Assistance Contract for the Elderly (PACE) and PACE Needs Enhancement Tier (PACENET). Secondary objectives included quantifying the number of patients successfully enrolled, number of brand-name cardiovascular medications impacted by enrollment, and estimated cost saved by patients after enrollment in PACE/PACENET.

Project Design

This prospective quality improvement project evaluated patients followed by the Heart Care team at a large academic medical center in Pennsylvania for guideline-directed medical therapy (GDMT) optimization and affordability from October 1, 2024, to March 1, 2025.

Methods

Patients with Medicare Part D plans with orders for prespecified brand-name cardiovascular medications were screened for PACE/PACENET eligibility and provided with enrollment information during their admission. After discharge, eligible patients received a follow-up telephone call to confirm or assist with enrollment.

Results

A total of 100 patients were included in this project. After the initial screening, 19 patients were enrolled, and 43 patients did not qualify for PACE/PACENET. Thirty-eight patients were determined to be eligible but not enrolled, and, after further criteria-based screening, 27 patients remained eligible for PACE/PACENET enrollment. Over the course of the project,
3 patients were enrolled in PACENET, impacting their access to 5 brand-name cardiovascular medications and saving the patients an estimated combined total of $579.65 per month.

Conclusions

Pharmacists play a critical role in identifying patients with financial burdens and facilitating access to cost-assistance programs. Health systems can incorporate strategies to identify medication affordability issues and assist with enrollment in prescription assistance programs as part of the transitions-of-care process.

Introduction

According to the World Health Organization, ischemic heart disease and stroke were the first and third leading causes of death around the world in 2021, respectively.1 By the year 2030, cardiovascular disease (CVD) is expected to be the leading cause of death in patients 65 years and older.2 The prevalence of CVD in patients 60 to 79 years old is 75% in the United States, with age being one of the most important risk factors for both CVD and its associated high health care burden.2,3 The prevalence of atrial fibrillation is expected to nearly triple by the year 2050 as the population of adults 65 years and older in the US continues to rapidly grow.4 Heart failure has reached global pandemic status, with an estimated increase in prevalence by 2030 to 8.5% of individuals in the US aged 65 to 70 years.5,6

An analysis of Medicare beneficiaries by Zhang et al showed that improved adherence to cardiovascular medications following a myocardial infarction was associated with a reduction in heart disease–related readmission rates within 6 to 12 months of discharge.7 However, a survey conducted by AARP in 2024 found that 38% of adults 65 years and older eligible for Medicare had avoided filling a prescription because of its cost or knew someone who had.8 These data indicate a potential associated risk between decreasing medication affordability and increasing hospitalizations among the Medicare population.

Many CVD treatment guidelines recommend 1 or more high-cost brand-name medications as first-line therapy. Since 2019, direct-acting oral anticoagulants (DOACs) have been recommended over warfarin for the treatment of nonvalvular atrial fibrillation because of their lower rates of major bleeding and stroke.9 Though DOAC utilization has increased, cost remains a significant barrier for patients who cannot afford the 25-fold difference in price.10 In acute coronary syndromes, Brilinta (AstraZeneca; ticagrelor) is generally recommended over other P2Y12 inhibitors for its reduced risk of death from vascular causes, myocardial infarction, or stroke.11 On average, Medicare patients pay $67.24 out of pocket per month for Brilinta.12 As of 2023, the standard of care for heart failure treatment includes a sodium-glucose cotransporter 2 inhibitor (SGLT2i), regardless of ejection fraction, and an angiotensin receptor–neprilysin inhibitor (ARNI) for most ejection fractions.13,14 Guideline-directed medical therapy (GDMT) with an SGLT2i, ARNI, β-blocker (BB), and mineralocorticoid receptor antagonist (MRA) has the greatest evidence for reducing morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF).15 The 2-year mortality rate is 35% for patients with HFrEF who are not on GDMT.6 A 2022 review found the median out-of-pocket cost of GDMT for Medicare recipients was $2217 annually. Less-preferred medication regimens, including a BB, MRA, and either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, cost approximately $159 annually.15

The Pharmaceutical Assistance Contract for the Elderly (PACE) and PACE Needs Enhancement Tier (PACENET) programs help qualified Pennsylvania residents, including those with Medicare Part D coverage, reduce out-of-pocket prescription costs. Patients 65 years and older who meet the limited-income requirements are eligible to receive brand-name medications for up to $9 per month with PACE or $15 per month with PACENET.16 In 2022, the PACE Application Center reached out to 190,700 eligible Pennsylvanians, of whom only 8900 submitted applications.17 That same year, over 2.8 million Pennsylvania residents were enrolled in Medicare, accounting for more than 22% of the total state population.18

Pharmacists involved in transitions of care are well positioned to intervene on medication safety, efficacy, and affordability issues that arise. By augmenting traditional inpatient management strategies with a transitions-of-care pharmacist, health systems can realize cost savings associated with readmissions and improve patient outcomes. A time-and-motion cost analysis conducted within 2 large academic medical centers in the US found the estimated cost of pharmacists’ interventions was $101 per hospitalization. Compared with the typical cost of an adverse drug event in older adults ($1200 to $2500) and a hospital readmission (> $15,000), the average cost of a multicomponent quality improvement intervention aimed at preventing readmission is just $554.19,20 With this investment, hospitals can see a 7% to 14% reduction in emergency department visits or readmissions.20,21 A core element of pharmacist-mediated transitions of care is assessing and optimizing medication regimens not only to align with evidence-based recommendations but also to ensure financial feasibility.19 Despite medication affordability being a common pharmacist intervention, there are limited data available detailing the impact of pharmacist-led medication cost-savings initiatives.

The academic medical center’s Heart Care team is a comprehensive care team of nurse navigators, nurse practitioners, cardiac rehabilitation specialists, resource care assistants, quality coordinators, and a clinical pharmacist. The Heart Care team’s mission is to assist in transitions of care to optimize patient outcomes. The role of the clinical pharmacist on the Heart Care team is to identify transitions-of-care patients and recommend evidence-based pharmacotherapeutic regimens.

The center’s Pharmacist Standard of Care, which was implemented in September 2024, is as follows:

  1. Patients who are admitted because of heart failure exacerbation are screened for optimization of GDMT.
  2. Patients who are admitted because of a suspected acute coronary syndrome event will have their antiplatelet therapy evaluated for clinical
    appropriateness.
  3. All patients are screened for affordability of medications.
    • Patients on brand-name cardiovascular medication(s) are screened for PACE/PACENET enrollment or eligibility based on criteria and have an intervention documented in the electronic health record.
    • Eligible but not enrolled patients are given enrollment information and added to a list in the electronic health record for follow-up within 4 weeks of being discharged on brand-name cardiovascular medication(s).
    • Patients on the list are followed up telephonically to confirm adherence to brand-name cardiovascular medication(s) and screen for PACE/PACENET enrollment and/or continued eligibility.

Methods

Project Design

This project was a prospective quality improvement project involving 100 patients followed by the Heart Care team from October 1, 2024, to March 1, 2025. The project protocol was determined to be exempt from institutional review board review. Patients 65 years and older who were eligible for Medicare Part D, were currently prescribed 1 or more prespecified brand-name cardiovascular medications, and met PACE/PACENET eligibility criteria for screening, per the Pharmacist Standard of Care, were included. Patients who were unsure whether they met PACE/PACENET eligibility criteria or unable to be contacted for follow-up were counted as eligible. The prespecified brand-name cardiovascular medications of interest were Eliquis (Bristol Myers Squibb, Pfizer; apixaban), Farxiga (AstraZeneca; dapagliflozin), Jardiance (Boehringer Ingelheim; empagliflozin), Xarelto (Johnson & Johnson; rivaroxaban), Entresto (Novartis; sacubitril/valsartan), and Brilinta. Patients were excluded if they were enrolled in the US Department of Health and Human Services’ Medicaid prescription benefit program, were enrolled in commercial insurance, had zero-dollar co-payments through their insurance, or were incarcerated. Data were collected and stored in a separate, password-protected file. Descriptive statistics were used for data analysis.

Objectives

The primary objective was to determine the percentage of Medicare Part D–eligible recipients who were admitted to the hospital, ordered 1 or more prespecified brand-name cardiovascular medications, and met PACE/PACENET criteria but were not enrolled in PACE/PACENET. Secondary objectives included determining the number of patients successfully enrolled in PACE/PACENET, quantifying the number of brand-name cardiovascular medications impacted after enrollment in PACE/PACENET, and estimating the cost saved for brand-name cardiovascular medications after enrollment in PACE/PACENET. Preenrollment costs were estimated using test claim data from Epic Willow as part of the academic medical center’s Meds to Beds price consultation service.

Statistical Analysis

All 100 screened patients were included in the statistical analysis. Descriptive statistics were used for the primary and secondary objectives, which were expressed as a percentage and number, respectively.

Results

Project Population

Of the 100 patients screened, 38 patients were eligible but not enrolled in PACE/PACENET after the initial screening. A total of 27 patients remained eligible after follow-up (Figure). Baseline characteristics of patients after the initial screening and follow-up are outlined in Table 1. Groups were comparable across age and sex distributions, with patients already enrolled in PACE/PACENET tending to be slightly older. Table 2 shows the distribution of brand-name cardiovascular medications and time spent conducting follow-up outreach to patients eligible but not enrolled in PACE/PACENET. The most common reason patients did not qualify for PACE/PACENET was a reported income above the threshold amount.

Outcomes

For the primary objective, 27% of Medicare Part D–eligible recipients admitted to the hospital and ordered 1 or more brand-name cardiovascular medications were determined to meet PACE/PACENET criteria but were not enrolled in PACE/PACENET (Figure). For the secondary objectives, a total of 3 of the 27 eligible patients (11%) who were eligible but not enrolled at screening became successfully enrolled in PACENET after discharge. Among these 3 patients, 5 brand-name medications were affected by enrollment and an estimated $579.65 per month was saved by enrollment (Table 3).

Discussion

In this prospective quality improvement project involving Medicare Part D–eligible patients followed by the Heart Care team and with orders for 1 or more brand-name cardiovascular medications, it appears the PACE/PACENET cost-assistance programs are underutilized. Nearly 30% of patients who were ordered at least 1 brand-name cardiovascular medication and met PACE/PACENET criteria were not enrolled. However, when patients were provided with enrollment information during admission and follow-up, 3 (11%) of the 27 eligible patients successfully enrolled in PACENET. Reasons for eligible patients not enrolling in PACE/PACENET included not calling PACE/PACENET yet, no longer being interested in enrollment, waiting until after taxes were filed, and waiting for family members to assist with the application. Eight patients could not be reached for follow-up.

All 3 patients who successfully enrolled in PACENET reported relying on family members to complete the application over the phone on their behalf, indicating a potential benefit to involving patients’ support systems to overcome barriers. Although PACE/PACENET eligibility assessments and applications can be completed over the phone to streamline service, patients are required to have a comprehensive list of their income sources and insurance information readily available. This requirement limits health care team members’ ability to assist with enrollment during admission, when both parties are physically present. Additionally, this project targeted recently hospitalized older patients with a significant cardiovascular disease burden and often additional underlying financial and social barriers. Therefore, it is crucial to educate patients thoroughly during admission, provide close follow-up, and leverage their support systems for assistance.

After enrollment, a combined estimate of $579.65 per month was saved in brand-name cardiovascular medication costs. Further, the average amount of time spent per follow-up call was only 6 minutes. The monthly cost savings observed with these 3 patients’ enrollment illustrate the profound impact that a pharmacist-driven initiative can have on improving sustained financial access to guideline-recommended pharmacotherapies without requiring a substantial time commitment.

Limitations

There were several limitations within the project. First, success was dependent upon patients’ cooperation, their level of health literacy, and the existence of a support system. Patients were responsible for completing the PACE/PACENET application independently, which is a lengthy and detailed process, and patients with poor health literacy and limited resources may have had difficulty applying. Second, it is difficult to accurately assess income in the inpatient setting, and patients may have incorrectly reported income above the eligibility threshold during the initial screening. Third, this project did not evaluate patients with commercial insurance or polypharmacy who were on generic or other brand-name medications and who may have benefited from PACE/PACENET enrollment. Finally, 3 eligible patients died before follow-up but were included in the preliminary analysis.

Future Directions

Future studies should include a multidisciplinary team comprising social workers, case managers, and transitional coordinators to aid with patient support and enrollment in available prescription assistance programs such as PACE/PACENET. Many clinical settings currently use embedded pharmacists and social workers as additional resources to increase access to medications and provide patient follow-up, both in person and by phone. In-person follow-up may result in higher patient engagement and enrollment rates. By educating members of the health care team on cost-assistance programs and expanding the patient population to include all PACE/PACENET–eligible patients across both inpatient and outpatient services, a greater impact on patient care could be seen.

Conclusion

The results of this project showed that cost-assistance programs such as PACE/PACENET are underutilized in the transitions-of-care setting and that a pharmacist-led initiative to increase identification and enrollment is beneficial for ensuring brand-name cardiovascular medications are affordable in the outpatient setting. Because many medications are becoming available as generic formulations, PACE/PACENET may help lower the costs of generic medications as well. This suggests a role for the heart failure transitions-of-care clinical pharmacist in facilitating medication affordability, which may lead to better adherence to GDMT, specifically in patients with a diagnosis of heart failure.

REFERENCES
  1. The top 10 causes of death. World Health Organization. Accessed June 23, 2026. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
  2. North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res. 2012;110(8):1097-1108. doi:10.1161/CIRCRESAHA.111.246876
  3. Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular risks associated with gender and aging. J Cardiovasc Dev Dis. 2019;6(2):19. doi:10.3390/jcdd6020019
  4. Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127(1):4-20. doi:10.1161/CIRCRESAHA.120.316340
  5. Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: an updated review. Card Fail Rev. 2023;9:e11. doi:10.15420/cfr.2023.05
  6. Bozkurt B, Ahmad T, Alexander KM, et al; Writing Committee Members. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America. J Card Fail. 2023;29(10):1412-1451. doi:10.1016/j.cardfail.2023.07.006
  7. Zhang Y, Kaplan CM, Baik SH, Chang CC, Lave JR. Medication adherence and readmission after myocardial infarction in the Medicare population. Am J Manag Care. 2014;20(11):e498-e505.
  8. Keenan TA. AARP poll: the burden of prescription drug costs: a survey of adults ages 50 and older. AARP Research. Published online August 28, 2024. doi:10.26419/res.00853.001
  9. Dayoub EJ, Ross JS, Shah ND, Dhruva SS. Evolution of Medicare formulary coverage changes for antithrombotic therapies after guideline updates. Circulation. 2019;140(14):1227-1230. doi:10.1161/CIRCULATIONAHA.119.040580
  10. Duvalyan A, Pandey A, Vaduganathan M, et al. Trends in anticoagulation prescription spending among Medicare Part D and Medicaid beneficiaries between 2014 and 2019. J Am Heart Assoc. 2021;10(24):e022644. doi:10.1161/JAHA.121.022644
  11. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):e18-e114. doi:10.1161/CIR.0000000000001038
  12. Brilinta cost and patient assistance programs. AstraZeneca. Accessed June 23, 2026. https://simplefill.com/patient-assistance-program/brilinta/
  13. Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(18):1835-1878. doi:10.1016/j.jacc.2023.03.393
  14. Heidenreich PA, Bozkurt B, Aguilar D, et al; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063
  15. Faridi KF, Dayoub EJ, Ross JS, Dhruva SS, Ahmad T, Desai NR. Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure. J Am Coll Cardiol. 2022;79(25):2516-2525. doi:10.1016/j.jacc.2022.04.031
  16. Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE). Paying for Senior Care. June 3, 2024. Accessed June 23, 2026. https://www.payingforseniorcare.com/pennsylvania/pace
  17. Pennsylvania Department of Aging. Annual report to the Pennsylvania General Assembly—January 1–December 31, 2022. Accessed June 23, 2026. https://www.pa.gov/content/dam/copapwp-pagov/en/aging/documents/publications/annual-reports/2022%20pace%20annual%20report.pdf
  18. Medicare in Pennsylvania. HealthInsurance.org. Accessed June 23, 2026. https://www.healthinsurance.org/medicare/pennsylvania/
  19. Ensing HT, Stuijt CC, van den Bemt BJ, et al. Identifying the optimal role for pharmacists in care transitions: a systematic review. J Manag Care Spec Pharm. 2015;21(8):614-636. doi:10.18553/jmcp.2015.21.8.614
  20. Tasseff N, Axtell S, Nixon B. Effect of extended pharmacist involvement in discharge transitions of care on hospital readmission rates: prospective, randomized, parallel arm design trial. J Am Coll Clin Pharm. 2024;7(1):8-14. doi:10.1002/jac5.1887
  21. Phatak A, Prusi R, Ward B, et al. Impact of pharmacist involvement in the transitional care of high-risk patients through medication reconciliation, medication education, and postdischarge call-backs (IPITCH study). J Hosp Med. 2016;11(1):39-44. doi:10.1002/jhm.2493

Related to this article